I started to have the same concerns, along with curiosity as to why there has not been a formal announcement regarding IBIS. I emailed Jane Greene. The next morning, I received a response. My follow up questions were responded to in the same day. I was impressed by her promptness. The following are the details:
.
As an ISIS shareholder, I am wondering why the IBIS division information
was not formally announced in a news release?
.
.
Dear Emil:
The Ibis division is still somewhat in a formative stage as a research
program. We will determine the appropriate time to formally introduce
it.
It is a program that has evolved to a large extent from our combinational
program, so while the effort is innovative, is it a continuation of
research efforts that have been underway for awhile.
Best regards, Jane Green
.
.
Then I replied this morning with a concern about the struggling stock price in light of others advancing, as well as timeframes for future news releases.
The following is the response, which I received in the same day.
.
.
Hello Emil:
I wish I could give you a good explanation for why our stock behaved
differently than many other biotech companies this week, but I cannot.
We
have not issued any negative news, and projects are progressing. It
would
be inappropriate to signal ahead of time when we are going to release
news,
so I cannot respond to that request. Our hope is that in a reasonable
time, the market will recognize Isis' value. Our focus right now is on
continuing to create value by advancing our clinical development programs
and by continuing to strengthen the technological foundation of the
company.
Best regards, Jane Green
.
Comments?
|
